Immutep (ASX:IMM) share price flying 20% on improving trials

The Immutep share price is flying today as the company reported improvements in trials relating to its leading drug IMP321.
The post Immutep (ASX:IMM) share price flying 20% on improving trials appeared first on Motley Fool Australia. –

row of piggy banks with large one receiving injection representing rising Immutep share price

The Immutep Ltd (ASX: IMM) share price is today flying as the company announced a number of results from its ongoing trials. The Immutep share price has gained a huge 20.45% today, rising to 26.5 cents at the time of writing.

What Immutep does

Immutep is a biotechnology company headquartered in Australia. Immutep focuses on personalised bio-therapeutic products for the treatment of cancer. Its main product is eftilagimod alpha (IMP321), a soluble fusion protein, which is in clinical development for the treatment of cancer. Immutep has two other clinical candidates (IMP701 and IMP731) that are fully licensed to major pharmaceutical partners, and a fourth candidate (IMP761) which is in pre-clinical development. 

The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014, the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. It is now dual listed with one listing on the ASX and another as Immutep ADS Representing 10 Ord Shs (NASDAQ: IMMP).

INSIGHT-004 trial

The Immutep share price is soaring higher today as it was announced that the company saw improving results from the INSIGHT-004 trial. The trial is evaluating the combination of Immutep’s lead product candidate, IMP321 with a human antibody (avelumab), in 12 patients with different solid tumours, primarily gastrointestinal.

In positive news for the biotech, 41.7% of patients showed a partial response to the combination therapy of IMP321 and avelumab (previously 33%). Furthermore, there was encouraging levels of anti-tumour activity signals in a variety of the cancer indications. These are usually not typically sensitive to immune checkpoint inhibitor (ICI) therapy.

On a final note, the combination of IMP321 and avelumab continues to be safe and well tolerated by patients.

TACTI-002 Study

The TACTI-002 study is being conducted in collaboration with Merck & Co., Inc. (NYSE: MRK). The study is evaluating the combination of IMP321 with Merck & Co’s Keytruda drug in patients with neck squamous cell carcinoma or lung cancer.

The study has produced three complete responses, with two in neck squamous cell carcinoma and one in lung cancer. A complete response indicated the complete disappearance of all lesions.

However it must be noted that, despite the improvement, the study has only produced a response in a total of 8 patients out of the 109 in the trial.

What now for the Immutep share price?

The improving results are great news for shareholders as the company seeks to return to its former highs. The Immutep share price has been on an impressive run since its lows in late March this year. The stock is up a huge 165% from its March low of 10 cents.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Immutep (ASX:IMM) share price flying 20% on improving trials appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!